Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus
- PMID: 1761072
- DOI: 10.1007/BF00626367
Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus
Abstract
Diabetes may alter the pharmacokinetics of aminopyrine and antipyrine, which are used to assess liver function. Caffeine has recently been used to test liver function, but the effect of diabetes on caffeine kinetics is not known. The kinetics of caffeine has been examined in patients with decompensated Type I and Type II diabetes and in two age- and sex-matched control groups. In both types of diabetes the apparent caffeine clearance, half-life, and apparent volume of distribution were similar to controls. It is concluded that decompensated diabetes does not influence the cytochrome P-448 mono-oxygenase system responsible for caffeine metabolism.
Similar articles
-
Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity.Pharmacotherapy. 2000 Feb;20(2):182-90. doi: 10.1592/phco.20.3.182.34775. Pharmacotherapy. 2000. PMID: 10678296 Clinical Trial.
-
Differential effect of type I and type II diabetes on antipyrine disposition in man.Eur J Clin Pharmacol. 1988;34(4):369-75. doi: 10.1007/BF00542438. Eur J Clin Pharmacol. 1988. PMID: 3402522
-
Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement.Pharmacol Toxicol. 2002 Mar;90(3):155-60. doi: 10.1034/j.1600-0773.2002.900308.x. Pharmacol Toxicol. 2002. PMID: 12071338 Clinical Trial.
-
Differential effect of type I and type II diabetes mellitus on antipyrine elimination.Methods Find Exp Clin Pharmacol. 1989 Dec;11(12):755-8. Methods Find Exp Clin Pharmacol. 1989. PMID: 2626081
-
Cytokines and diabetes: the final step? Involvement of TNF-alpha in both type I and II diabetes mellitus.Horm Metab Res. 1994 Oct;26(10):447-9. doi: 10.1055/s-2007-1001730. Horm Metab Res. 1994. PMID: 7851865 Review. No abstract available.
Cited by
-
Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug-drug Interactions.Clin Pharmacokinet. 2024 Jun;63(6):831-845. doi: 10.1007/s40262-024-01383-2. Epub 2024 May 31. Clin Pharmacokinet. 2024. PMID: 38819713
-
Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.Clin Pharmacokinet. 2012 Aug 1;51(8):481-99. doi: 10.2165/11631900-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22668340 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical